The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials

Yuping Li¹,²*, Mengzhuo Hou²*, Guangyu Lu³,⁴, Natalia Ciccone², Xingdong Wang¹, Hengzhu Zhang¹

¹ Department of Neurosurgery, The Clinical Medical College of Yangzhou University, Yangzhou, China, 2 Neurosurgical Research, Department of Neurosurgery, Ludwig-Maximilians University of Munich, Munich, Germany, 3 Department of Preventive Medicine, Medical College of Yangzhou University, Yangzhou University, China, 4 Institute of Public Health, Medical School, Ruprecht-Karls-University, Heidelberg, Germany

☯ These authors contributed equally to this work.
* zhanghengzhu@sina.com

Abstract

Background and Purpose
Although bevacizumab (BV) has been approved as second-line therapy for recurrent glioblastoma (GB), the efficacy and safety of BV for patients with newly diagnosed GB remain unclear.

Methodology/Principal Findings
We systematically searched electronic databases (PubMed, EMBASE, OVID, etc.) to identify related studies published from January 1966 and August 2016. Eight randomized controlled trials including a total of 2,185 patients with GB were included. We found that the median progression-free survival (PFS) was higher in the BV group than in the standard therapy (ST) group (pooled hazard ratio, 0.73; 95%CI, 0.62–0.86; P = 0.0001). Compared with ST, BV improved the PFS rate at 6 months (OR 3.33, 95% CI 2.73–4.06, p < 0.00001) and 12 months (OR 2.10, 95% CI 1.74–2.54, p < 0.00001). There were no significant differences in median overall survival between the BV and ST groups (OR, 1.01; 95%CI, 0.83–1.23; P = 0.95). The BV group had higher survival rates at 6 months (OR 1.41; 95% CI, 1.09–1.84; P = 0.01) and 12 months (OR 1.23; 95% CI, 1.02–1.48; P = 0.03), but a low survival rate at the 36-month follow-up (OR, 0.57; 95% CI, 0.32–0.98; P = 0.04). For the incidence of adverse events, three adverse outcomes were found to be significantly different between BV and ST groups, including hypertension (8.37% vs. 1.62%, p < 0.000001), proteinuria (7.65% vs. 0%, p < 0.001), and fatigue (14.54% vs. 9.01%, p = 0.05).

Conclusions/Significance
Our study indicates that combination of BV with ST for newly diagnosed GB did not improve the median overall survival but result in longer median PFS, maintaining the quality of life
and functional status. However, the long-term use of BV is associated with a higher incidence of adverse events and mortality.

**Study Registration**

This research was registered at PROSPERO. (Registration Number: CRD42016038247).

---

**Introduction**

Glioblastoma (GB), the most common primary malignant brain tumor in adults, has a dismal prognosis, with a median survival of 14 to 16 months [1]. Even with the best available standard therapies (surgical resection followed by radiotherapy and temozolomide), the prognosis of patients with GB remains low [2,3]. When GB recurs, the median overall survival is typically 3 to 9 months, and available therapies have a limited impact on outcome [4]. Therefore, development of new therapies is essential to improve the overall survival and prognosis of patients with newly diagnosed GB. During the past decade, a large number of targeted therapeutic agents have been developed and evaluated. GB is highly vascular and typically overexpresses vascular endothelial growth factor (VEGF), which promotes tumor angiogenesis, contributing to tumor growth and progression [5–7]. Several clinical trials have suggested that VEGF could be a therapeutic target [8,9]. The U.S. Food and Drug Administration (FDA) approved bevacizumab (BV), a humanized monoclonal antibody to VEGF, for second-line treatment of recurrent GB [10,11]. Despite its prolongation of progression-free survival (PFS) in patients with recurrent GB, the impact of BV on overall survival remains undefined.

Several clinical trials have reported that treatment with combinations of BV and other chemotherapeutic agents results in stable responses and a prolonged 6-month PFS rate in patients with recurrent high-grade glioma, but do not significantly prolong overall survival (OS), compared with previous trials [12–16]. Furthermore, most of the complications caused by the toxicity of the combined chemotherapy led to discontinuation of treatment for patients with GB [17]. In 2009, Zhang et al. conducted a meta-analysis to assess the efficacy and safety of BV alone compared with BV and irinotecan for recurrent GB [18]. The results indicated that the combination of BV and irinotecan may increase the rate of discontinuation and that there was no obvious improvement in overall survival in patients with recurrent GB. Furthermore, this research included only nonrandomized control trials or small-sample retrospective studies. The data from low-quality research results in significant heterogeneity.

From 2009 onward, several randomized controlled trials (RCTs) were conducted to assess the effectiveness of BV for newly diagnosed GB [19–26]. Therefore, it became necessary to conduct a meta-analysis to assess the clinical efficacy of BV compared with standard therapy (ST) or other chemotherapies for newly diagnosed GB and to evaluate the safety and adverse effects of these combinations.

**Materials and Methods**

There is no necessary for ethic approval in this meta-analysis, which mainly based on the published studies. This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [27].
Literature Search and Study Selection

Two reviewers (GY.L and MZ.H) performed the literature searching on the BV for patients with newly diagnosed GB to identify relevant articles published between January 1966 and August 2016. Electronic search used “bevacizumab”, “avastin”, “chemotherapy”, “glioblastoma”, “newly diagnosed glioblastoma”, “GB” in Mesh and free terms. We searched PubMed, EMBASE, and the Cochrane Library to identify relevant studies. Manual searches were performed to relevant journal and reference lists of retrieved articles. Two independent reviewers (YP.L and MZ.H) assessed the literature based on the titles and abstracts to identify potentially relevant articles. Full versions of all relevant articles were obtained and inspected.

Inclusion Criteria and Exclusion Criteria

The inclusion criteria were used for selecting the potential studies: (1) RCTs compare the standard treatment with or without BV for patients with newly diagnosed GB; (2) the patients were adults; (3) the main clinical outcomes and complications were reported; and (4) at least 6 months follow-up.

The exclusion criteria of studies were: (1) review; (2) lack of randomization; (3) data could not be extracted; (4) insufficient clinical data; (5) duplicate papers.

Data Extraction and Qualitative Assessment

The relevant data from selected studies were independently extracted by 2 reviewers (GY.L and YP.L) as follows: (1) Publishing time, (2) mean age, number of patient, (3) study quality, (4) Follow up, (5) main results, including overall survival (OS) and progression-free survival (PFS), and (6) secondary outcomes, adverse events incidence. Two observers assessed methodological quality of the included studies. The GRADE approach was introduced to evaluate the overall methodological quality of including studies as recommended by Cochrane Handbook for Systematic Review of Interventions [28].

Statistical Methods

Meta-analysis was performed with RevMan software (version 5.1; The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). The hazard ratio (HR) with 95% confidence intervals (CIs) was used to assess main outcomes of the studies, including median OS, median PFS. HRs and their corresponding SEs were directly extracted from studies. If the study did not report a HR but gave the data in the form of the survival curve, survival rates at certain specified times were extracted from them for the reconstruction of the HR estimate and its SEs. The odds ratio (OR) with 95% confidence intervals (CIs) was used to assess the rate of OS and PFS at different follow-ups (6, 12, 24, and 36 months). Statistical significance was accepted as p value less than 0.05. In order, Cochrane Q test (α = 0.05) was performed to analyze the heterogeneity. If the result of the test of the heterogeneity was P > 0.05, the fixed-effect model was used. If the result of heterogeneity test was P < 0.05, then the pooled ORs were analyzed using the random effects model. Publication bias was evaluated with Egger’s regression test in which P value less than 0.10 were considered representative of statistically significant publication bias.

Results

Description of the Studies

Fig 1 is a flowchart describing the study selection and inclusion process. The primary search yielded 2,172 potentially relevant articles (Fig 1). Of these, 2161 were excluded after reading
titles and abstracts. Two independent reviewers (Y.P.L and H.Z.Z) then reviewed the full texts of the remaining 12 articles. Four more studies were excluded. Finally, we identified 8 RCTs including a total of 2,185 patients with newly diagnosed GB (Table 1) [19–26]. Sample size ranged from 54 to 921. Six studies were published in English [19–24] and two in Chinese [25,26]. These articles were published between 2011 and 2015. Details of the treatment and functional outcome measures are summarized in Table 1.
The Median PFS and PFS Rate

Five studies presented the data of median PFS comparing BV with ST group [19,20,22–24]. Since the significant difference was observed in heterogeneity test (I^2 = 52, P = 0.08), the

| Study                | Inclusion criteria | Age (y) | Cases (n/M) | Treatment | Outcome | Side-effect | Follow-up (m) |
|----------------------|--------------------|---------|-------------|-----------|----------|-------------|---------------|
| Albert Lai 2011      | age > 18 years     | 57.4    | 59.4        | 70/39     | BE       | RT          | OS            | Y             | 42            |
|                      | newly diagnosed GB |         |             |           |          |             |               |               |
|                      | KPS >60            |         |             |           |          |             |               |               |
| MR. Gilbert 2014     | age > 18 years     | -       | -           | 312       | BE       | RT          | OS            | Y             | 30            |
|                      | newly diagnosed GB |         |             |           |          |             |               |               |
|                      | KPS>70             |         |             |           |          |             |               |               |
| OL. Chinot 2014      | age > 18 years     | 57      | 56          | 458       | BE       | RT          | OS            | Y             | 32            |
|                      | newly diagnosed GB |         |             |           |          |             |               |               |
|                      | KPS >70            |         |             |           |          |             |               |               |
| OL. Chinot 2014      | ages from 18 and   | 60.2    | 60.9        | 60/34     | BE       | RT          | OS            | Y             | 24            |
|                      | 70 y               |         |             |           |          |             |               |               |
|                      | KPS>50             |         |             |           |          |             |               |               |
|                      | histologically     |         |             |           |          |             |               |               |
|                      | confirmed          |         |             |           |          |             |               |               |
| B. Chauffert 2014    | age > 18 years     | 55.9    | 59.5        | 30/17     | BE       | IRI         | Response Rate | Y             | 31            |
|                      | newly diagnosed GB |         |             |           |          |             |               |               |
|                      | KPS >60            |         |             |           |          |             |               |               |
| U Herrlinger 2013    | newly diagnosed GB | 56      | 56          | 116/80    | BE       | RT          | OS            |               | 36            |
|                      | KPS >70            |         |             |           |          |             |               |               |
|                      | age > 18 years     |         |             |           |          |             |               |               |
| JIA. Carlson 2015    | age > 18 years     | 55.9    | 59.5        | 30/17     | BE       | hypo-IMRT   | OS            | Y             | 60            |
|                      | newly diagnosed GB |         |             |           |          | hypo-IMRT   |               |               |
|                      | KPS >60            |         |             |           |          |             |               |               |
| KF. Hofland 2014     | age > 18 years     | 62      | 59          | 32/21     | BE       | IRI         | Response Rate | Y             | 31            |
|                      | newly diagnosed GB |         |             |           |          |             |               |               |
| Jiaqi Wang 2013      | newly diagnosed GB | 53.6    | 54.7        | 27/16     | BE       | RT          | RECIST        | Y             | 24            |
|                      | KPS >60            |         |             |           |          |             |               |               |

GB: Glioblastoma; KPS: Karnofsky performance status; RT: radiotherapy; TMZ: temozolomide; BV: bevacizumab; OS: overall survival; PFS: progression-free survival; GHS: Global Health Status; GoL: quality of life; Y: yes;
random-effects model was applied to analyze data. The pooled HR was 0.73 (95%CI, 0.62–0.86; P = 0.0001), as shown in Fig 2.

Eight studies reported the PFS rate at different follow-ups comparing BV with ST group [19–26]. No statistically significant heterogeneity was observed between studies, I^2 = 3% at 6 months, 0% at 12 months, and 23% at 24 months; so the fixed effect model was applied. The pooled OR of PFS was 3.33 at 6 months (95%CI, 2.73–4.06; P < 0.00001), 2.10 at 12 months (95%CI, 1.74–2.54; P < 0.00001), 0.85 at 24 months (95%CI, 0.53–1.36; P = 0.48), and 0.53 at 36 months follow-ups (95%CI, 0.21–1.34; P = 0.18). (Fig 3)

The Median OS and Survival Rate

Five studies presented the data of median OS [19,20,22–24]. The heterogeneity test showed significant differences in each study (I^2 = 66, P = 0.02). Then we applied the random-effects model to analyze the data. The pooled HR of median OS was 1.01 (95%CI, 0.83–1.23; P = 0.95) as shown in Fig 4.

All included studies [19–26] reported the data of survival rate in different follow-up endpoints. The test of total heterogeneity showed no significant differences (I^2 = 21, P = 0.18). The fixed-effects model was applied. The pooled OR of survival rate was 1.41 (95%CI, 1.09–1.84; P = 0.01) at 6 month, 1.23 (95% CI, 1.02–1.48; P = 0.03) at 12 month, 1.09 (95% CI, 0.89–1.35; P = 0.40) at 24 month. Moreover, we noted that low survival rate in BV group at 36 month, and the OR was 0.57 (95% CI, 0.32–0.98; P = 0.04). (Fig 5)

Safety of BV for Patients with Newly Diagnosed GB

Of included trials, five trials provided data of AEs incidence [19,20,22–24]. From these events, three adverse outcomes were found to be significantly different between bevacizumab and standard treatment groups, including hypertension (8.37% vs. 1.62%, p < 0.000001), proteinuria (7.65% vs. 0%, p < 0.001), fatigue (14.54% vs. 9.01%, p = 0.05), as shown in Table 2. The incidence of all severe AEs also showed significant between BV and ST group, as shown in Fig 6. There was significant trend toward with regard to BV therapy and high severe AEs incidence (P = 0.033).

Qualitative Assessment and Publication Bias

The quality of the studies included in this meta-analysis is shown in Table 1. It can be seen from the funnel plot that the publication bias was low to moderate regarding PFS and OS (Figs 7 and 8).
Discussion

GB is an aggressive malignant brain tumor with a poor prognosis. Despite the use of some anti-angiogenesis treatments, there remains no successful therapy [1,2]. The average survival
time is only 14 months after diagnosis [3]. A major clinical problem is the extent to which the glioma cells invade adjacent brain tissue, making complete surgical removal impossible [29]. Some research has indicated that GB has multistep tumorigenesis ability to activate the vascularization of brain tissue to form new blood vessels, which contribute to tumor growth and proliferation [29,30]. VEGF has shown promise as a therapeutic target in the treatment of brain tumors [31]. Bevacizumab was developed to directly inhibit VEGF-associated angiogenic effects by blocking activation of the VEGF receptor (VEGF-R) [32,33]. Recently, BV was used as second-line therapy for recurrent GB in some clinical trials [34–37]. To date, no meta-analysis has investigated the effects of BV on the prognosis of newly diagnosed GB.

The principal findings of our meta-analysis can be summarized as follows: (1) BV combined with standard treatments could improve the median PFS of patients with newly diagnosed GB and the PFS rate in short-term follow-up (6 and 12 months). (2) There is no significant difference in median overall survival between patients treated with BV and those treated with ST; however, more survivors were observed in the BV group in early follow-up (<12), with this trend reversing at 36 months. (3) The incidence of severe adverse effects was higher after BV therapy than after ST.

Our results indicate that BV could prolong the median PFS of patients with newly diagnosed GB as compared with a ST group. More patients had attained PFS in the BV group than in the ST group at 6 months (78.26% vs. 53.19%) and 12 months (41.26% vs. 27.34%) follow-up; at the 2-year follow-up, we found the PFS rates of the BV and ST groups were equivalent. Furthermore, one study reported a decreased PFS rate in the BV group compared with the ST group at 3 years. On the basis of the aforementioned evidence, we conclude that BV improves the short-term PFS rate (<12 months). These results are consistent with previous clinical trials. The AVAglio trial reported median PFS durations of 10.6 months in the BV group and 6.2 months in the ST group [23], and the RTOG 0825 trial obtained the same results for PFS duration (10.7 months in the BV group vs. 7.3 months in the ST group) [22]. However, these two large RCTs did not report PFS rates at 3 years of follow-up. The decreased PFS was observed after long-term application of BV (>3 years), which might be caused by BV resistance, chronic comorbid conditions, or side effects. Additional clinical trials are needed to clarify this issue.

Our study indicated that BV did not improve the median overall survival of patients with newly diagnosed GB. This finding coincides with those of the AVAglio, RTOG 082512, and GLARIUS trials, indicating approximately equivalent overall survival (OS) for the BV and ST groups (11.1% vs. 11.7%, p = 0.59) [22–24]. However, comparison of OS rates at different follow-up points revealed more survivors in the BV group early in follow-up (<12 months), with this trend reversing at 36 months. Our data indicate that with prolonged use of BV, patients with GB exhibited worse neurocognition and higher mortality, compared with controls.
# Anti-Angiogenesis Therapy for GB

**Fig 5.** The pooled analysis of OS rate comparing BV with ST in patients with GB at different follow-ups.

doi:10.1371/journal.pone.0168264.g005

| Study or Subgroup       | BV Events | BV Total | ST Events | ST Total | Weight | Odds Ratio M-H, Fixed, 95% CI | Odds Ratio M-H, Fixed, 95% CI |
|-------------------------|-----------|----------|-----------|----------|--------|-------------------------------|-------------------------------|
| Overall Survival Rate   |           |          |           |          |        |                               |                               |
| at 6 months             |           |          |           |          |        |                               |                               |
| Albert Lai 2011         | 69        | 97       | 110       | 0.2%     | 9.25   | [1.18, 72.25]                |                               |
| B. Chauffet 2014        | 42        | 60       | 62        | 2.5%     | 1.00   | [0.46, 2.18]                 |                               |
| Chanjuan Chen 2015      | 40        | 42       | 42        | 0.3%     | 3.33   | [0.63, 17.57]                |                               |
| J. A. Carlson 2015      | 28        | 30       | 24        | 0.3%     | 1.17   | [0.15, 8.92]                 |                               |
| MR. Gilbert, 2014       | 263       | 312      | 255       | 8.1%     | 1.14   | [0.74, 1.74]                 |                               |
| OL. Chinot 2014         | 421       | 458      | 405       | 6.5%     | 1.63   | [1.06, 2.52]                 |                               |
| U. Herrlinger 2013      | 109       | 116      | 51        | 0.8%     | 0.92   | [0.23, 3.69]                 |                               |
| Subtotal (95% CI)       | 1088      | 1064     | 18.8%     | 1.41    | [1.09, 1.84]                 |                               |
| Total events            | 972       | 910      |           |          |        |                               |                               |
| Heterogeneity: Chi² = 6.81, df = 6 (P = 0.34); I² = 12% |
| Test for overall effect: Z = 2.57 (P = 0.01) |
| at 12 months            |           |          |           |          |        |                               |                               |
| Albert Lai 2011         | 54        | 71       | 83        | 110      | 3.0%   | 1.10                          | [0.54, 2.23]                 |
| B. Chauffet 2014        | 26        | 60       | 28        | 60       | 3.2%   | 0.87                          | [0.43, 1.79]                 |
| J. A. Carlson 2015      | 22        | 30       | 18        | 26       | 1.0%   | 1.22                          | [0.38, 3.90]                 |
| Jiaqi Wang 2013         | 26        | 27       | 24        | 27       | 0.2%   | 3.25                          | [0.32, 33.41]                |
| MR. Gilbert, 2014       | 200       | 312      | 192       | 309      | 13.9%  | 1.09                          | [0.79, 1.51]                 |
| OL. Chinot 2014         | 322       | 458      | 293       | 463      | 17.3%  | 1.37                          | [1.04, 1.81]                 |
| U. Herrlinger 2013      | 98        | 116      | 42        | 54       | 1.8%   | 1.56                          | [0.69, 3.51]                 |
| Subtotal (95% CI)       | 1073      | 1049     | 40.3%     | 1.23    | [1.02, 1.48]                 |                               |
| Total events            | 748       | 680      |           |          |        |                               |                               |
| Heterogeneity: Chi² = 3.11, df = 6 (P = 0.79); I² = 0% |
| Test for overall effect: Z = 2.17 (P = 0.03) |
| at 24 months            |           |          |           |          |        |                               |                               |
| Albert Lai 2011         | 22        | 70       | 50        | 110      | 5.3%   | 0.55                          | [0.29, 1.03]                 |
| B. Chauffet 2014        | 9         | 60       | 3         | 60       | 0.5%   | 3.35                          | [0.86, 13.07]                |
| J. A. Carlson 2015      | 7         | 30       | 6         | 26       | 1.0%   | 1.01                          | [0.29, 3.52]                 |
| MR. Gilbert, 2014       | 47        | 312      | 50        | 309      | 8.5%   | 0.92                          | [0.60, 1.42]                 |
| OL. Chinot 2014         | 139       | 458      | 118       | 463      | 16.4%  | 1.27                          | [0.95, 1.70]                 |
| U. Herrlinger 2013      | 28        | 116      | 11        | 54       | 2.3%   | 1.24                          | [0.57, 2.73]                 |
| Subtotal (95% CI)       | 1046      | 1022     | 34.0%     | 1.09    | [0.89, 1.35]                 |                               |
| Total events            | 252       | 238      |           |          |        |                               |                               |
| Heterogeneity: Chi² = 9.01, df = 5 (P = 0.11); I² = 44% |
| Test for overall effect: Z = 0.84 (P = 0.40) |
| at 36 months            |           |          |           |          |        |                               |                               |
| Albert Lai 2011         | 8         | 70       | 25        | 110      | 3.4%   | 0.44                          | [0.19, 1.04]                 |
| OL. Chinot 2014         | 11        | 458      | 15        | 463      | 2.9%   | 0.73                          | [0.33, 1.62]                 |
| U. Herrlinger 2013      | 2         | 116      | 2         | 54       | 0.5%   | 0.46                          | [0.06, 3.33]                 |
| Subtotal (95% CI)       | 644       | 627      | 6.9%      | 0.57    | [0.32, 0.98]                 |                               |
| Total events            | 21        | 42       |           |          |        |                               |                               |
| Heterogeneity: Chi² = 0.80, df = 2 (P = 0.67); I² = 0% |
| Test for overall effect: Z = 2.02 (P = 0.04) |
| Total (95% CI)          | 3851      | 3762     | 100.0%    | 1.17    | [1.04, 1.32]                 |                               |
| Total events            | 1993      | 1870     |           |          |        |                               |                               |
| Heterogeneity: Chi² = 27.93, df = 22 (P = 0.18); I² = 21% |
| Test for overall effect: Z = 2.60 (P = 0.009) |
| Test for subgroup differences: Chi² = 9.25, df = 3 (P = 0.03), I² = 67.6% |
Until now, our knowledge of the mechanism underlying the pro-tumor effect of long-term BV treatment has been limited. One clinical study reported that nearly half of patients with GB treated with BV had a low response rate [38]. The rebound of tumor invasion and metastasis was observed by radiography [39]. Several experiments in animals have found more perivascular invasion, more peritumoral satellite lesions, and higher expression of invasion-related proteins with long-term BV treatment as compared with short-term BV treatment [40,41]. Lucio Eterovic et al. found that with increasing concentration of BV administered, U87 glioma cells secreted greater amounts of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-12, and activated other angiogenic pathways, promoting the migration and invasion of tumor cells [40]. More importantly, in this research, BV was combined with MMP inhibitor (GM6001) in

![Fig 6. The incidence of all severe AEs in patients with newly diagnosed GB.](doi:10.1371/journal.pone.0168264.g006)

Table 2. The adverse events of patients with newly diagnosed GB between BV and ST groups.

| Adverse Event            | n (studies) | BV group | ST group | OR       | P       |
|--------------------------|-------------|----------|----------|----------|---------|
|                          |             | n(III-IV) | n(total) | n(III-IV) | n(total) |
| Cerebral ischemia        | 2           | 7        | 127      | 1        | 56      | 3.21 [0.39, 26.71] | 0.28 |
| Cerebral Hemorrhage      | 4           | 9        | 848      | 7        | 750     | 2.30 [0.96, 5.54]  | 0.06 |
| Diarrhea                 | 3           | 5        | 154      | 0        | 83      | 6.14 [0.34, 112.49] | 0.22 |
| Neutropenia              | 3           | 31       | 344      | 19       | 316     | 1.55 [0.86, 2.80]  | 0.15 |
| Nausea and vomit         | 2           | 11       | 287      | 5        | 260     | 2.03 [0.70, 5.93]  | 0.19 |
| Fatigue                  | 2           | 48       | 330      | 21       | 233     | 1.72 [1.00, 2.96]  | 0.05 |
| Hypertension             | 4           | 71       | 848      | 12       | 739     | 5.54 [2.98, 10.29] | <0.000001 |
| Infection                | 3           | 16       | 154      | 4        | 83      | 2.29 [0.74, 7.09]  | 0.15 |
| Proteinuria              | 2           | 33       | 431      | 0        | 560     | 94.24 [5.76, 1542.53] | <0.001 |
| Thromboembolic event     | 4           | 56       | 805      | 55       | 766     | 0.97 [0.66, 1.42]  | 0.86 |
| Anemia                   | 3           | 9        | 344      | 7        | 317     | 1.19 [0.44, 3.23]  | 0.73 |

doi:10.1371/journal.pone.0168264.t002
the glioma mouse model. The results indicated that those therapies could prolong survival and suppress tumor progression [40]. Recently, results from animal research suggested that minocycline reduces glioma growth by inducing glioma autophagy [42]. In addition, an ongoing clinical trial found that use of radiation, followed by BV and minocycline, to treat recurrent GB may improve the effect of long-term BV treatment. (ClinicalTrials.gov Identifier: NCT01580969)

Drug resistance was considered another factor influencing the effectiveness of BV treatment for GB. BV was able to inhibit the VEGF—VEGFR signal pathway to suppress tumor growth [43]. Although this could reduce cerebral oxygen delivery, which up regulates the expression of HIF-10, it will result in a rebound in the expression of VEGF genes [44,45]. In addition, a multidirectional cytokine, placental growth factor (PlGF), which is homologous to VEGF, can promote the proliferation and migration of endothelial cells. When VEGF is inhibited, endothelial cells upregulate the expression of PlGF to maintain tumor-associated vascular growth [46]. Recently, several researchers found that some cytokines overexpressed in glioma cells after BV treatment contribute to angiogenesis, including platelet-derived growth factor, fibroblast growth factor, interleukin-8 and -10, and angiopoietin-1 [47–49].

Fig 7. The funnel plot of PFS on patients with newly diagnosed GB.

doi:10.1371/journal.pone.0168264.g007
The adverse events of BV might affect the quality of life and prognosis of patients with GB. The most common adverse events of BV included abdominal pain, headache, fatigue, hypertension, diarrhea, neutropenia, wound infections, cerebral hemorrhage or ischemia, nausea and vomiting, thromboembolism, and anemia. To assess the incidence of severe adverse effects (AEs) in BV treatment of adults newly diagnosed with GB, we extracted all BV-associated severe AEs from the five studies included in this meta-analysis. We found that those treated with BV had an increased symptom burden and incidence of severe AEs. In a previous meta-analysis assessing the risk of adverse vascular events in patients newly diagnosed with GB, BV therapy was not found to significantly influence the risk of all-cause discontinuation, thrombocytopenia, deep vein thrombosis, and pulmonary embolism in adult patients newly diagnosed with GB [50]. The authors, however, did report a trend toward significance with respect to BV therapy and the risk of pulmonary embolism [50]. Therefore, in patients under treatment with BV, care should be taken to monitor blood pressure, blood clotting function, kidney function, and other indicators.

Fig 8. The funnel plot of OS on patients with newly diagnosed GB.

doi:10.1371/journal.pone.0168264.g008
Limitation
The present study has several limitations. First, because only eight RCTs were included, small sample size and highly selected patient populations could generate selective bias. Second, there were insufficient data on mutation status and BV resistance. Third, most of the studies included studies reported the OS and PFS rates only within 2 years of follow-up. Considering the long-term survival rate, further studies reporting OS rates at 3 years or longer follow-ups are needed to clarify this issue. Fourth, although all the included studies used ST combined with BV for newly diagnosed GB, two studies administered BV combined with irinotecan and one study combined BV with hypofractionated intensity modulated radiation therapy in the experimental groups, which may have caused heterogeneity in comparisons. Fifth, new therapies are continuing to show the potential benefits for patients with newly diagnosed GB, such as carmustine wafer (CW). A meta-analysis from Chowdhary SA et al. indicated that CW treatment could significantly improve the overall survival and survival rate of patients with newly diagnosed or recurrent high-grade GB [51]. Therefore, further studies are required to investigate the effect of BV combined with other therapies for newly diagnosed GB, such as CW. Sixth, relevant factors could influence the prognosis of patients with newly diagnosed GB, including patient age, gender, obesity, steroid use, and smoking history. Because such individual data were lacking, this study did not assess these factors.

Conclusions
In summary, our study indicates that BV therapy does not appear to improve median OS in patients with newly diagnosed GB, whereas it prolongs median PFS. We also found that BV therapy improves the PFS and OS rates at the 6- and 12-months follow-ups. However, at 36 months, the decreased OS rate and high incidence of severe AEs in those treated with BV make quality of life an issue.

Supporting Information
S1 Checklist. PRISMA Checklist.

Author Contributions
Conceptualization: YL HZ.
Data curation: YL HZ.
Formal analysis: YL MH GL.
Funding acquisition: YL.
Investigation: MH.
Methodology: GL MH.
Project administration: XW HZ.
Resources: GL.
Software: GL MH.
Supervision: XW.
Validation: NC HZ.
Visualization: YL.

Writing – original draft: YL NC.

Writing – review & editing: HZ YL MH GL NC XW.

References

1. Stupp R, Pavlidis N, Jelic S. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol. 2005; 16 Suppl 1:64–5.

2. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies formalignant gliomas. Lancet neurol. 2008; 7: 1152–1160. doi: 10.1016/S1474-4422(08)70260-6 PMID: 19007739

3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncol. 2009; 10: 459–466. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895

4. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83: 588–593. doi: 10.1054/bjoc.2000.1316 PMID: 10944597

5. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005; 15: 297–310. PMID: 16389942

6. Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. J Neurooncol. 2006; 78: 281–293. doi: 10.1007/s11060-005-9097-6 PMID: 16554966

7. Jain RK, Tomaso E, Duda DG, Loefler JS, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8: 610–622. doi: 10.1038/nrn2175 PMID: 17643088

8. Dumphich Matthias and Theiss Carsten. VEGF in the nervous system: an important target for research in neurodevelopmental and regenerative medicine. Neural Regen Res. 2015; 10: 1725–1726. doi: 10.4103/1673-5374.170287 PMID: 26807091

9. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol. 2011; 6: 2. doi: 10.1186/1748-717X-6-2 PMID: 2124925

10. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27: 740–745. doi: 10.1200/JCO.2008.16.3055 PMID: 19114704

11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733–4740. doi: 10.1200/JCO.2008.19.8721 PMID: 19720927

12. Gil MJ, de Las Peñas R, Reynés G, Balarán C, Peréz-Segura P, García-Velasco A, et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-Cancer Drugs. 2012; 23: 659–665. doi: 10.1097/CAD.0b013e3283534d3e PMID: 22834799

13. Moller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, et al. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol. 2012; 51: 797–804. doi: 10.3109/02841866.2012.681063 PMID: 22548369

14. Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother. 2011; 12: 825–833. doi: 10.1517/14656566.2011.566558 PMID: 21385110

15. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in Molecular Medicine. 2007; 13: 223–230. doi: 10.1016/j. molmed.2007.04.001 PMID: 17462954

16. Paldino MJ, Desjardins A, Friedman HS, Vredenburgh JJ, Barbioriak DP. A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. Br J Radiol. 2012; 85: 382–389. doi: 10.1259/bjr/24774491 PMID: 21224297

17. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al. The relationship between six month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007; 9: 29–38. doi: 10.1215/1528033X-2006-025 PMID: 17108063
18. Zhang Guobin, Huang Shengyue, Wang Zhongcheng. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci. 2009; 19: 1636–1640.

19. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011; 29: 142–148. doi: 10.1200/JCO.2010.30.2729 PMID: 21135282

20. Chauvet M, Feuvret L, Bonnette F, Tailandier L, Frappaz D, Tallaia H, et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemotherapy compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMA-VIR study from ANOCEF. Tumor Biol. 2014; 25: 1442–1447. doi: 10.1093/annonc/mdu148 PMID: 24723487

21. Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, et al. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol. 2015; 123: 251–257. doi: 10.1007/s11060-015-1791-4 PMID: 25920710

22. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 699–708. doi: 10.1056/NEJMoa1308573 PMID: 24552317

23. Chinot OL, Wick W, Mason W, Henriksen R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370: 709–722. doi: 10.1056/NEJMoa1309345 PMID: 24552318

24. Herrlinger U, Schafer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Non-methylated Glioblastoma: The Randomized GLAURIUS Trial. J Clin Oncol. 2016; 34: 1611–1619. doi: 10.1200/JCO.2015.63.4691 PMID: 26976423

25. Chen CJ, Wang JQ, Liang Y, Yu XJ, Ouyang S. Clinical Effect of Temozolomide Plus Avastin Combined with Concurrent Radiotherapy on Postoperative High-grade Glioma. Anti-tumor Pharmacology. 2015; 5: 126–9. [In Chinese]

26. Wang JQ, Liang Y, Ouyang Z, Liu C, Ouyang S, Tang HY. Analysis of the Curative Effects of Bevacizumab Integrated with Temozolomide in the Treatment of Glioblastoma. Anti-tumor Pharmacology. 2013; 3: 274–277. [In Chinese]

27. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6: e1000100. doi: 10.1371/journal.pmed.1000100 PMID: 19621070

28. Higgins J, Churchill R, Cumpston M, Chandler J. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. http://www.cochrane.org/training/cochrane-handbook. Accessed 2013 June 15.

29. Stupp R, Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005; 5: 198–206. PMID: 15865885

30. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med. 2005; 352: 997–1003. doi: 10.1056/NEJMoa043331 PMID: 15758010

31. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005; 438: 932–936. doi: 10.1038/nature04475 PMID: 16355210

32. Bergetts G and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8: 592–603. doi: 10.1038/nrc2442 PMID: 18650835

33. Trevisan E, Bertero L, Bosa C, Magistrello M, Pellerino A, Rudà R, et al. Antiangiogenic therapy of brain tumors: the role of bevacizumab. Neurol Sci. 2014; 35: 507–514. doi: 10.1007/s10072-014-1627-6 PMID: 24442487

34. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253–1259. doi: 10.1158/1078-0432.CCR-06-2309 PMID: 17317837

35. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcelli J, Herndon JE, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent glioma. Neuro Oncol. 2010; 12: 1300–1310. doi: 10.1093/neuonc/noon090 PMID: 20716591

36. Hasselbach B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010; 12: 508–516. doi: 10.1093/neuonc/noq063 PMID: 20406901
37. Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neuro Oncol. 2012; 107: 155–164.

38. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009; 9: 444. doi: 10.1186/1471-2407-9-444 PMID: 20015387

39. Grant JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010; 12: 233–242. doi: 10.1093/neuonc/nop027 PMID: 20167811

40. Poez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15: 220–231. doi: 10.1016/j.ccr.2009.01.027 PMID: 19249680

41. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011; 108: 3749–3754.

42. Hu F, Ku MC, Markovic D, a Dyke OD, Lehnardt S, Synowitz M, et al. Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline. Int J Cancer. 2014; 135: 2569–2578. doi: 10.1002/ijc.28908 PMID: 24752463

43. Lueio-Eterovik AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009; 15: 4589–4599. doi: 10.1158/1078-0432.CCR-09-0575 PMID: 19567599

44. Hormigo A, Ding BS, Raft S. A target for antiangiogenic therapy: vascular endothelium derived from glioblastoma. PNAS Nat Acad Sci USA. 2011; 108: 4271–4272.

45. Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, et al. Induction of interleukin-8 preserves the angiogenic response in HIV-1 a deficient colon cancer cells. Nat Med. 2005; 11: 992–997. doi: 10.1038/nm1294 PMID: 16127434

46. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, et al. Anti-PIGF inhibits growth of VEGF(R)-inhibitor resistant tumors without affecting healthy vessels. Cell. 2007; 131: 463–475. doi: 10.1016/j.cell.2007.08.038 PMID: 17981115

47. Femando NT, Koch M, Rothrock C, Gollogly LK, Amore PA, Ryeom S, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res. 2008; 14: 1529–1539. doi: 10.1158/1078-0432.CCR-07-4126 PMID: 18316578

48. Norden AD, Young GS, Setayesh K, Muzikansky A, Kluftas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70: 779–787. doi: 10.1212/01.wnl.0000304121.57857.38 PMID: 18316689

49. Narayana A, Kelly P, Golfinos J, Parker E, Johnson C, Knopp E, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009; 110: 173–180. doi: 10.3171/2008.4.17492 PMID: 18834263

50. Li Xiaoming, Huang Rongzhong, Xu Zhongye. Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analyis. Sci Rep. 2011; 5: 14698.

51. Chowdhary SA, Ryken T, Newton HB. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neurooncol. 2015; 122: 367–382. doi: 10.1007/s11060-015-1724-2 PMID: 25630625